OSLO, Norway--(BUSINESS WIRE)--Nordic Nanovector ASA (OSE:NANO), a company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology, will host a Capital Markets Day on Tuesday, 17 November 2015 in Oslo for investors, analysts and members of the press.
Please register by 10 November by e-mail to firstname.lastname@example.org
The Capital Markets Day will take place at:
Meeting Room: TEATERSALEN
The event will provide an opportunity to learn more about the Company’s corporate strategy, its lead product Betalutin® as a potential new treatment for non-Hodgkin’s lymphoma (NHL), and the development and commercialisation plans for this novel Antibody-Radionuclide-Conjugate (ARC), as well as future opportunities for value creation.
|08:15 - 08:45 Registration: breakfast buffet upon arrival|
|08:45 - 08:55 Opening remarks||CEO Luigi Costa|
|08:55 - 09:05 Welcome from the Board of Directors||Chairman Ludvik Sandnes|
|09:05 - 09:50 The science behind Betalutin: why is it unique?||Dr. Roy Larsen, PhD|
|09:50 - 10:35 The data behind Betalutin: reasons to believe||Dr. Arne Kolstad, MD, PhD|
|10:35 - 10:45 Q&A|
|10:45 - 10:55 Coffee break|
|10:55 - 11:40 What is NHL, how is it treated, what is the unmet need?||Prof. Tim Illidge, BSc PhD MRCP FRCR FRCPath|
|11:40 - 12:25 Beginning with the goal in mind: our strategic approach to|
|Betalutin’s clinical development||CBO Marco Renoldi, MD|
|12:25 - 12:45 Nordic Nanovector strategic outlook & vision||CEO Luigi Costa|
|12:45 - 13:00 Closing remarks and Q&A||CEO Luigi Costa|
|13:00 - 14:00 End of meeting: lunch upon departure|
The presentations will be available at www.nordicnanovector.com in the section: Investor Relations/Reports and Presentation/Presentations/2015 from following the meeting. No new material information will be presented.
Biographies of external speakers:
Dr Roy H. Larsen was a founder of Anticancer Therapeutic Invention AS (later Algeta ASA) and is the inventor of more than ten classes of patents/patent applications, including those related to Algeta’s radium-223 and thorium-227 technology. He is author of more than 50 peer reviewed papers in scientific journals and with a PhD and postdoctoral experience in radiopharmaceutical chemistry from University of Oslo, Norway and Duke University, Durham, NC, USA, respectively. He served as managing director and later Chief Scientific Officer of Algeta from 1997-2006, and was also a board member from 1997-2003. He was one of the founders of and the Chairman of the Board of Directors of Nordic Nanovector from 2009-2014, and is a member of the Board of Directors of Nordic Nanovector.
Dr Arne Kolstad is senior consultant in medical oncology and radiotherapy at Oslo University Hospital Radiumhospitalet and he also holds a research position funded by the Norwegian Cancer Society. He is chairman of the Norwegian Lymphoma Group and leader of Oslo University Hospital focus area Cancer Immunotherapy. His main scientific interests are radioimmunotherapy, cellular therapies and cancer vaccines in malignant lymphoma. He published two papers as first author in Blood in 2014, one as principal investigator of a Nordic radioimmunotherapy trial in mantle cell lymphoma and another as principal investigator of a cancer vaccine trial in follicular lymphoma. He was a visiting scientist in Mark Kaminski’s group at the University of Michigan in 1998-1999 and visiting professor in Ron Levy’s group at Stanford University in 2007-2008. He has published more than 60 original papers in international journals and was awarded the Ragnar Mørks prize for cancer research at Oslo University Hospital Radiumhospitalet in 2014. He was also awarded a prize for best original article at Oslo University Hospital in 2014. Dr Kolstad is a member of Nordic Nanovector’s Scientific Advisory Board.
Prof. Timothy Martin Illidge is professor of Targeted Therapy and Oncology and Honorary Consultant in Oncology, University of Manchester and Christie Hospital NHS Foundation Trust, UK. He received his medical degree (MB BS) from Guy's Hospital Medical School, London, and a PhD from the University of Southampton for his work in the field of lymphoma. He completed research fellowships as Cancer Research UK (CRUK) Senior Clinical Research Fellow and was appointed Senior Lecturer and Honorary Consultant in Oncology at Southampton University Hospitals NHS Trust in 1999. He was a awarded a US Senior Fulbright fellowship and a Winston Churchill Fellowship which enabled him to work as part of the lymphoma team at Stanford University, USA, in 1998. Prof. Illidge’s research is based on developing new antibody-based therapies for lymphoma. His clinical interest is in lymphoma where he has led many early phase and late clinical trials and is recognised as an international expert in antibodies and radioimmunotherapy applied to lymphoma, and he has published extensively (more than 100 publications). He serves on the central steering group of the National Cancer Research Institute lymphoma group, has represented the UK at international workshops in lymphoma and is a member of the American Society of Hematologists. He is also a Member of the Royal College of Physicians, Fellow of the Royal College of Radiologists and Fellow of the Royal College of Pathologists. Prof. Illidge is one of the two chairmen of Nordic Nanovector’s Scientific Advisory Board.
About Nordic Nanovector
Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018. Betalutin® comprises a tumour-seeking anti-CD37 antibody (HH1) conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications. Further information about the Company can be found at www.nordicnanovector.com
This information was brought to you by Cision http://news.cision.com